Overview
Nicolas Chapuis practices in Paris, France. Mr. Chapuis is rated as an Experienced expert by MediFind in the treatment of Glucose-6-Phosphate Dehydrogenase Deficiency. His top areas of expertise are Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML), Leukemia, and Chronic Myelomonocytic Leukemia (CMML).
His clinical research consists of co-authoring 86 peer reviewed articles. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 2 articles in the study of Glucose-6-Phosphate Dehydrogenase Deficiency.
Locations
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Advanced
- Acute Myeloid Leukemia (AML)Mr. Chapuis isAdvanced. Learn about Acute Myeloid Leukemia (AML).
- LeukemiaMr. Chapuis isAdvanced. Learn about Leukemia.
- Myelodysplastic Syndrome (MDS)Mr. Chapuis isAdvanced. Learn about Myelodysplastic Syndrome (MDS).
- Experienced
- Alpha ThalassemiaMr. Chapuis isExperienced. Learn about Alpha Thalassemia.
- Anaplastic Large Cell LymphomaMr. Chapuis isExperienced. Learn about Anaplastic Large Cell Lymphoma.
- AnemiaMr. Chapuis isExperienced. Learn about Anemia.
- Chronic Myelomonocytic Leukemia (CMML)Mr. Chapuis isExperienced. Learn about Chronic Myelomonocytic Leukemia (CMML).
- Congenital Hemolytic AnemiaMr. Chapuis isExperienced. Learn about Congenital Hemolytic Anemia.
- COVID-19Mr. Chapuis isExperienced. Learn about COVID-19.